Arsine toxicity treated with red blood cell and plasma exchanges

Constance Danielson, Julie Houseworth, Elaine Skipworth, Daniel Smith, Leo McCarthy, Kristine Nanagas

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

BACKGROUND: Acute toxicity due to inhalation of arsine gas (AsH 3) has no known antidote. Exchange transfusion may be beneficial, and dialysis is often required because arsine may cause acute intravascular hemolysis and renal failure. A patient with arsine toxicity has recently been treated by both red blood cell exchange (RBC-E) and plasma exchange (PE) therapy and our experience is reported. CASE REPORT: A 46-year-old man was accidentally and unknowingly exposed to arsine gas while observing an industrial procedure. Within 6 hours he developed fatigue, nausea, vomiting, and tingling in his extremities and voided dark urine. He quickly developed renal failure secondary to acute arsine toxicity (arsenic level, 1250 μg/L). Laboratory findings were a hematocrit level of 24 percent; blood urea nitrogen and creatinine, 84 and 5.5 mg per dL, respectively; bilirubin, 9.1 mg per dL; indirect bilirubin, 6.8 mg per dL; haptoglobin, less than 6 (normal, 30-200); and lactic dehydrogenase, 10,413 units per L (normal, 265-580). An emergent 1-vol RBC-E transfusion by continuous-flow method revealed dramatic black, grossly hemolyzed plasma. After two additional RBC-E and two PE and daily hemodialysis, he completely recovered over the course of 1 month. CONCLUSION: Patients with arsine toxicity resulting in intravascular hemolysis should receive RBC-E as soon as possible. In addition, PE may be beneficial in removing the components of RBC lysis and further reducing arsenic levels.

Original languageEnglish (US)
Pages (from-to)1576-1579
Number of pages4
JournalTransfusion
Volume46
Issue number9
DOIs
StatePublished - Sep 2006
Externally publishedYes

Fingerprint

Plasma Exchange
Erythrocytes
Arsenic
Hemolysis
Bilirubin
Renal Insufficiency
Gases
Erythrocyte Transfusion
Antidotes
Haptoglobins
Blood Urea Nitrogen
Hematocrit
Nausea
Inhalation
Vomiting
Fatigue
Renal Dialysis
arsine
Dialysis
Creatinine

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Arsine toxicity treated with red blood cell and plasma exchanges. / Danielson, Constance; Houseworth, Julie; Skipworth, Elaine; Smith, Daniel; McCarthy, Leo; Nanagas, Kristine.

In: Transfusion, Vol. 46, No. 9, 09.2006, p. 1576-1579.

Research output: Contribution to journalArticle

Danielson, C, Houseworth, J, Skipworth, E, Smith, D, McCarthy, L & Nanagas, K 2006, 'Arsine toxicity treated with red blood cell and plasma exchanges', Transfusion, vol. 46, no. 9, pp. 1576-1579. https://doi.org/10.1111/j.1537-2995.2006.00931.x
Danielson, Constance ; Houseworth, Julie ; Skipworth, Elaine ; Smith, Daniel ; McCarthy, Leo ; Nanagas, Kristine. / Arsine toxicity treated with red blood cell and plasma exchanges. In: Transfusion. 2006 ; Vol. 46, No. 9. pp. 1576-1579.
@article{c19b7b3636594fe983efc0b5f7a74761,
title = "Arsine toxicity treated with red blood cell and plasma exchanges",
abstract = "BACKGROUND: Acute toxicity due to inhalation of arsine gas (AsH 3) has no known antidote. Exchange transfusion may be beneficial, and dialysis is often required because arsine may cause acute intravascular hemolysis and renal failure. A patient with arsine toxicity has recently been treated by both red blood cell exchange (RBC-E) and plasma exchange (PE) therapy and our experience is reported. CASE REPORT: A 46-year-old man was accidentally and unknowingly exposed to arsine gas while observing an industrial procedure. Within 6 hours he developed fatigue, nausea, vomiting, and tingling in his extremities and voided dark urine. He quickly developed renal failure secondary to acute arsine toxicity (arsenic level, 1250 μg/L). Laboratory findings were a hematocrit level of 24 percent; blood urea nitrogen and creatinine, 84 and 5.5 mg per dL, respectively; bilirubin, 9.1 mg per dL; indirect bilirubin, 6.8 mg per dL; haptoglobin, less than 6 (normal, 30-200); and lactic dehydrogenase, 10,413 units per L (normal, 265-580). An emergent 1-vol RBC-E transfusion by continuous-flow method revealed dramatic black, grossly hemolyzed plasma. After two additional RBC-E and two PE and daily hemodialysis, he completely recovered over the course of 1 month. CONCLUSION: Patients with arsine toxicity resulting in intravascular hemolysis should receive RBC-E as soon as possible. In addition, PE may be beneficial in removing the components of RBC lysis and further reducing arsenic levels.",
author = "Constance Danielson and Julie Houseworth and Elaine Skipworth and Daniel Smith and Leo McCarthy and Kristine Nanagas",
year = "2006",
month = "9",
doi = "10.1111/j.1537-2995.2006.00931.x",
language = "English (US)",
volume = "46",
pages = "1576--1579",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Arsine toxicity treated with red blood cell and plasma exchanges

AU - Danielson, Constance

AU - Houseworth, Julie

AU - Skipworth, Elaine

AU - Smith, Daniel

AU - McCarthy, Leo

AU - Nanagas, Kristine

PY - 2006/9

Y1 - 2006/9

N2 - BACKGROUND: Acute toxicity due to inhalation of arsine gas (AsH 3) has no known antidote. Exchange transfusion may be beneficial, and dialysis is often required because arsine may cause acute intravascular hemolysis and renal failure. A patient with arsine toxicity has recently been treated by both red blood cell exchange (RBC-E) and plasma exchange (PE) therapy and our experience is reported. CASE REPORT: A 46-year-old man was accidentally and unknowingly exposed to arsine gas while observing an industrial procedure. Within 6 hours he developed fatigue, nausea, vomiting, and tingling in his extremities and voided dark urine. He quickly developed renal failure secondary to acute arsine toxicity (arsenic level, 1250 μg/L). Laboratory findings were a hematocrit level of 24 percent; blood urea nitrogen and creatinine, 84 and 5.5 mg per dL, respectively; bilirubin, 9.1 mg per dL; indirect bilirubin, 6.8 mg per dL; haptoglobin, less than 6 (normal, 30-200); and lactic dehydrogenase, 10,413 units per L (normal, 265-580). An emergent 1-vol RBC-E transfusion by continuous-flow method revealed dramatic black, grossly hemolyzed plasma. After two additional RBC-E and two PE and daily hemodialysis, he completely recovered over the course of 1 month. CONCLUSION: Patients with arsine toxicity resulting in intravascular hemolysis should receive RBC-E as soon as possible. In addition, PE may be beneficial in removing the components of RBC lysis and further reducing arsenic levels.

AB - BACKGROUND: Acute toxicity due to inhalation of arsine gas (AsH 3) has no known antidote. Exchange transfusion may be beneficial, and dialysis is often required because arsine may cause acute intravascular hemolysis and renal failure. A patient with arsine toxicity has recently been treated by both red blood cell exchange (RBC-E) and plasma exchange (PE) therapy and our experience is reported. CASE REPORT: A 46-year-old man was accidentally and unknowingly exposed to arsine gas while observing an industrial procedure. Within 6 hours he developed fatigue, nausea, vomiting, and tingling in his extremities and voided dark urine. He quickly developed renal failure secondary to acute arsine toxicity (arsenic level, 1250 μg/L). Laboratory findings were a hematocrit level of 24 percent; blood urea nitrogen and creatinine, 84 and 5.5 mg per dL, respectively; bilirubin, 9.1 mg per dL; indirect bilirubin, 6.8 mg per dL; haptoglobin, less than 6 (normal, 30-200); and lactic dehydrogenase, 10,413 units per L (normal, 265-580). An emergent 1-vol RBC-E transfusion by continuous-flow method revealed dramatic black, grossly hemolyzed plasma. After two additional RBC-E and two PE and daily hemodialysis, he completely recovered over the course of 1 month. CONCLUSION: Patients with arsine toxicity resulting in intravascular hemolysis should receive RBC-E as soon as possible. In addition, PE may be beneficial in removing the components of RBC lysis and further reducing arsenic levels.

UR - http://www.scopus.com/inward/record.url?scp=33748294185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748294185&partnerID=8YFLogxK

U2 - 10.1111/j.1537-2995.2006.00931.x

DO - 10.1111/j.1537-2995.2006.00931.x

M3 - Article

VL - 46

SP - 1576

EP - 1579

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 9

ER -